

## DAFTAR PUSTAKA

- Adliana, R., & Wahid, R. S. A. (2023). Pemeriksaan Urin Lengkap dengan Alat Dirui FUS-2000 di Laboratorium Patologi Klinik RSUD Abdoel Wahab Sjahranie Samarinda. *JSN : Jurnal Sains Natural*, 1(3), 56–63. <https://doi.org/10.35746/jsn.v1i3.383>
- Andriani, G., Harlita, T. D., & Lamri, L. (2023). Identifikasi Bakteri Yang Dapat Menyebabkan Infeksi Saluran Kemih Pada Urine Pengguna Pantyliner. *Jambura Journal of Health Sciences and Research*, 5(3), 851–861. <https://doi.org/10.35971/jhsr.v5i3.20579>
- Ariwijaya, M., & Suwitra, K. (2007). Prevalensi, Karakteristik dan Faktor-Faktor yang Terkait Dengan Infeksi Saluran Kemih Pada Penderita Diabetes Melitus Yang Rawat Inap. *Journal of Internal Medicine*, 8(2), 1–16.
- Bettcher, C. M., Campbel, E., Petty, L. A., Rew, K. T., Zelnik, J. C., & Lane, G. I. (2021). Ambulatory Urinary Tract Infection (UTI) in Adults, Pregnant Women and Minors Key Points Diagnosis (Figure 1). *University of Michigan Health System, Table* 2,1–36. <http://michmed-clinical.policystat.com/policy/7109696/>.
- Hadawayah, A., Sukma, P., Resnhaleksmana, E., Khusuma, A., & Jiwintarum, Y. (2024). *Penentuan Hasil Mikroskopis Infeksi Saluran Kemih Metode Pewarnaan Gram dengan Menggunakan Perlakuan Urine Sentrifugasi dan Tanpa Sentrifugasi*. 3(2), 74–81.
- Kanan, M. (2019). Isolasi dan Identifikasi Biokimiawi Bakteri Patogen pada Saluran Pencernaan Lalat Hijau (Chryzomya megacheppala). *Jurnal Kesmas Untika Luwuk : Public Health Journal*, 10(1), 31–40. <https://doi.org/10.51888/phj.v10i1.6>
- Kranz, J., Bartoletti, R., Bruyère, F., Cai, T., Geerlings, S., Köves, B., Schubert, S., Pilatz, A., Veeratterapillay, R., Wagenlehner, F. M. E., Bausch, K., Devlies, W., Horváth, J., Leitner, L., Mantica, G., Mezei, T., Smith, E. J., & Bonkat, G. (2024). European Association of Urology Guidelines on Urological Infections: Summary of the 2024 Guidelines. *European Urology*, 86(1), 27–41. <https://doi.org/10.1016/j.eururo.2024.03.035>
- Lase, D. M., Tarigan, R. V. B., & Situmorang, P. R. (2023). Analisis Jumlah Leukosit Dan Eritrosit Pada Urine Lengkap Pasien Infeksi Saluran Kemih (Isk) Di Rumah Sakit Santa Elisabeth Medan Tahun 2023. *Journal of Indonesian Medical Laboratory and Science (JoIMedLabS)*, 4(2), 95–103. <https://doi.org/10.53699/joimedlabs.v4i2.153>
- Lestari, I., Pestariati, P., & Astuti, S. S. E. (2023). Deteksi Gen Tem (Temoneira) dari Isolat Klinis Escherichia Coli Penghasil Extended Spectrum Beta Lactamases (ESBL) Pasien Penderita Infeksi Saluran Kemih. *Malahayati Nursing Journal*, 5(1), 173–183. <https://doi.org/10.33024/mnj.v5i1.7832>
- Molekuler, B. B., Kedokteran, F., Lampung, U., Mikrobiologi, B., Kedokteran,

- F., Lampung, U., Biologi, B., Matematika, F., Alam, P., & Lampung, U. (2024). *Infeksi Saluran Kemih Akibat Penggunaan Kateter pada Pasien Rawat Inap di Rumah Sakit Urinary Tract Infection Due To Catheter Use In Hospitalized Patients*. 14, 2268–2274.
- Naid, T., Mangerangi, F., & Almahdaly, H. (2014). Pengaruh Penundaan Waktu Terhadap Hasil Urinalisis Sedimen Urin. *Jurnal Ilmiah As-Syifaa*, 6(2), 212–219. <https://doi.org/10.33096/jifa.v6i2.51>
- Nursamsu, N., & Febriliant, M. R. (2020). Wanita Usia 31 Tahun dengan Infeksi Saluran Kemih Berulang dan Rejeksi Transplan Ginjal: Suatu Laporan Kasus. *Jurnal Penyakit Dalam Indonesia*, 6(4), 204. <https://doi.org/10.7454/jpdi.v6i4.245>
- Pardede, S. O. (2018). Infeksi pada Ginjal dan Saluran Kemih Anak: Manifestasi Klinis dan Tata Laksana. *Sari Pediatri*, 19(6), 364. <https://doi.org/10.14238/sp19.6.2018.364-74>
- Paula, A., Saldanha, P., & Ismawatie, E. (2024). *PLENARY HEALTH : JURNAL KESEHATAN PARIPURNA Volume 1 Issue 3 2024 Page 400-405*
- PREVALENSI ESCHERICHIA COLI PADA PENDERITA INFEKSI SALURAN KEMIH DI RS GUIDO VALADARES TAHUN 2021 – 2022*. 1(3), 400–405.
- R. Chenari, M., Gooran, S., Zarghami, A., & Fazeli, F. (2012). Assessment of Urine Analysis Diagnostic Role: A Cross-Sectional Study in South Eastern of Iran. *Open Journal of Urology*, 02(04), 227–231. <https://doi.org/10.4236/oju.2012.24041>
- Rosana, Y., Ocviyanti, D., Halim, M., Harlinda, F. Y., Amran, R., Akbar, W., Billy, M., & Akhmad, S. R. P. (2020). Urinary Tract Infections among Indonesian Pregnant Women and Its Susceptibility Pattern. *Infectious Diseases in Obstetrics and Gynecology*, 2020. <https://doi.org/10.1155/2020/9681632>
- Selifiana, N., Irwanti, D., & Lisni, I. (2023). Evaluasi Penggunaan Antibiotik pada Pasien Infeksi Saluran Kemih di Salah Satu Rumah Sakit Kota Bandung. *Jurnal Ners*, 7(1), 284–292. <https://doi.org/10.31004/jn.v7i1.13209>
- Teguh Firdaus, & Rina Yunita. (2021). Urinary Tract Infection Bacterial at RSUP H. Adam Malik Medan in 2019: an Overview Study. *Sumatera Medical Journal*, 4(1), 1–7. <https://doi.org/10.32734/sumej.v4i1.5849>
- Triyani, N. N., Arsana, I. N., & Sudaryati, N. uh G. (2023). Infeksi Saluran Kemih Pada Pasien Diabetes Melitus. *Jurnal Widya Biologi*, 13, 64–70. <https://doi.org/10.32795/widyabiologi.v13i02.3565>
- Widianingsih, M., & Jesus, A. M. de. (2018). Isolasi Escherichia coli dari Urine Pasien Infeksi Saluran Kemih. *Journal of Biology*, 11(2), 99–108. <http://dx.doi.org/10.15408/kauniyah.v11i2.5899>
- Widianingsih, M., & Marcos De Jesus, A. (2018). ISOLASI Escherichia coli

dari urine pasien infeksi saluran kemih di rumah sakit bhayangkara kediri  
isolation of escherichia coli from urine of patients of urinary tract infection  
in bhayangkara kediri hospital. *Journal of Biology*, 11(2), 99–108.  
<http://dx.doi.org/10.15408/kauniyah.v11i2.5899>

Widyastuti, R., Tunjung, E., & Purwaningsih, nur vita. (2018). Modul praktikum  
urinalisis dan cairan tubuh. *Universitas Muhammadiyah Surabaya*, 1–68.

## **LAMPIRAN 1**

### **INFORMED CONSENT**

Assalamualaikum wr.wb Selamat pagi/siang Bapak/Ibu.

Nama saya Novia Rahma Bay dari Poltekkes Kemenkes Medan. Saya akan melakukan penelitian berjudul "Identifikasi Bakteri Patogen pada Pasien penderita Infeksi Saluran Kemih (ISK) di Laboratorium Bunda Thamrin Tahun 2025."

Tujuan dari penelitian ini adalah untuk mengidentifikasi jenis bakteri patogen yang terdapat pada sampel urin pasien penderita Infeksi Saluran Kemih (ISK). Hasil dari penelitian ini diharapkan dapat memberikan informasi ilmiah yang bermanfaat dalam bidang mikrobiologi dan kesehatan masyarakat.

Jika Bapak/Ibu bersedia menjadi partisipan dalam penelitian ini, sampel urin yang telah dikumpulkan sebelumnya untuk pemeriksaan rutin laboratorium akan digunakan untuk proses identifikasi bakteri. Tidak ada tindakan tambahan seperti pengambilan darah atau prosedur medis lainnya yang akan dilakukan.

Partisipasi Bapak/Ibu bersifat sukarela, dan tidak akan dikenakan biaya apapun selama proses penelitian berlangsung. Seluruh data dan identitas pribadi Bapak/Ibu akan dijaga kerahasiaannya dan hanya digunakan untuk keperluan penelitian ini.

Bapak/Ibu bebas menolak atau mengundurkan diri kapan saja, tanpa akan mempengaruhi pelayanan laboratorium yang Bapak/Ibu terima di Laboratorium Klinik Bunda Thamrin.

Penelitian ini tidak menimbulkan risiko langsung bagi Bapak/Ibu. Jika ada pertanyaan lebih lanjut atau hal-hal yang ingin didiskusikan terkait penelitian ini, Bapak/Ibu dapat menghubungi saya secara langsung:

**Nama : Novia Rahma Bay**  
**Instansi : Poltekkes Kemenkes Medan**  
**Kontak : 082343735805**

Jika Bapak/Ibu telah membaca dan memahami penjelasan ini, serta bersedia menjadi responden dalam penelitian, mohon untuk mengisi dan menandatangani Lembar Persetujuan yang tersedia.

Terima kasih atas perhatian dan kesediaan Bapak/Ibu. Wassalamu'alaikum warahmatullahi wabarakatuh.

Medan, 22 April 2025

Peneliti

(Novia Rahma Bay)

## **LEMBAR PERSETUJUAN SETELAH PENJELASAN**

Saya yang bertanda tangan dibawah ini:

Nama : \_\_\_\_\_

Umur : \_\_\_\_\_

Alamat : \_\_\_\_\_

No.Telp/Hp : \_\_\_\_\_

Setelah mempelajari dan mendapatkan penjelasan yang sejelas-jelasnya mengenai penelitian yang berjudul “Pola Resistensi Antibiotik terhadap Bakteri *Escherichia coli* yang Diisolasi dari Urin Penderita ISK di Laboratorium Klinik Bunda Thamrin” dan setelah mengetahui dan menyadari sepenuhnya resiko yang mungkin terjadi, dengan cara sadar dan tanpa paksaan dengan ini saya menyatakan bahwa saya bersedia dengan sukarela menjadi subjek penelitian tersebut dan patuh akan ketentuan-ketentuan yang dibuat peneliti. Jika sewaktu-waktu ingin berhenti, saya berhak untuk tidak melanjutkan penelitian ini tanpa ada sanksi apapun.

Yang menyatakan

Peneliti

( \_\_\_\_\_ )

(Novia Rahma Bay)

Saksi

( \_\_\_\_\_ )

## LAMPIRAN 2

### SURAT IZIN PENELITIAN

 <p>Nomor : KH.02.04/F.XXII.12/ <u>265</u> /2025 Perihal : Izin Penelitian</p>	<p><b>Kementerian Kesehatan</b> <b>Direktorat Jenderal</b> <b>Sumber Daya Manusia Kesehatan</b> Politeknik Kesehatan Medan Jalan Jamin Ginting KM. 13,5 Medan, Sumatera Utara 20136 Telp (061) 8368633 https://poltekkes-medan.ac.id</p>	<p>22 April 2025</p>																												
<p>Kepada Yth : Bapak/Ibu Pimpinan RSU Bunda Thamrin Medan Di _____ Tempat</p> <p>Dengan ini kami sampaikan, dalam rangka penulisan Karya Tulis Ilmiah untuk memenuhi persyaratan Ujian Akhir Program (UAP) Jurusan Teknologi Laboratorium Medis diperlukan penelitian.</p> <p>Dalam hal ini kami mohon, kiranya Bapak / Ibu bersedia memberi kemudahan terhadap mahasiswa/i kami.</p> <table border="1" data-bbox="552 1012 1266 1417"><thead><tr><th>No</th><th>Nama</th><th>NIM</th><th>Judul Penelitian</th></tr></thead><tbody><tr><td>1</td><td>Anugrah Napitupulu</td><td>P07534022055</td><td>Identifikasi Bakteri Staphylococcus Aureus Pada Penderita Infeksi Saluran Kemih Di RSU Bunda Thamrin Medan</td></tr><tr><td>2</td><td>Annisa Salsabila Siregar</td><td>P07534022054</td><td>Identifikasi Bakteri Proteus Mirabilis Pada Penderita Infeksi Saluran Kemih di RSU Bunda Thamrin Medan</td></tr><tr><td>3</td><td>Loveny Tamara Turnip</td><td>P07534022120</td><td>Identifikasi Bakteri Klebsiella Pneumonia Pada Penderita Isk di RSU Bunda Thamrin</td></tr><tr><td>4</td><td>Reisa Diah Salsabila</td><td>P07534022081</td><td>Pola Resistensi Antibiotik Terhadap Escherichia Coli Yang Diisolasi Dari Urin Penderita Isk di Laboratorium Bunda Thamrin</td></tr><tr><td>5</td><td>Novia Rahma bay</td><td>P07534022079</td><td>Identifikasi Bakteri Patogen Pada Pasien Penderita Infeksi Saluran Kemih Di Laboratorium Bunda Thamrin</td></tr><tr><td>6</td><td>Melisa Dermiyenti</td><td>P07534022122</td><td>Identifikasi Bakteri Escherichia Coli Pada Penderita Infeksi Saluran Kemih Di RSU Bunda Thamrin Medan</td></tr></tbody></table> <p>Untuk izin Penelitian di RSU Bunda Thamrin Medan .Hal-hal yang berhubungan dengan kegiatan tersebut adalah tanggung jawab mahasiswa/i.</p> <p>Demikianlah surat ini disampaikan, atas bantuan dan kerjasama yang baik diucapkan terima kasih.</p> <p style="text-align: center;">Ketua Jurusan TLM Nita Andriani Lubis, S.Si, M.Biomed NIP. 198012242009122001</p> <p style="text-align: center;"></p> <p style="text-align: center;"><i>Dokumen ini telah ditandatangani secara elektronik menggunakan sertifikat elektronik yang diterbitkan oleh Balai Besar Sertifikasi Elektronik (BSxE), Badan Siber dan Sandi Negara</i></p>			No	Nama	NIM	Judul Penelitian	1	Anugrah Napitupulu	P07534022055	Identifikasi Bakteri Staphylococcus Aureus Pada Penderita Infeksi Saluran Kemih Di RSU Bunda Thamrin Medan	2	Annisa Salsabila Siregar	P07534022054	Identifikasi Bakteri Proteus Mirabilis Pada Penderita Infeksi Saluran Kemih di RSU Bunda Thamrin Medan	3	Loveny Tamara Turnip	P07534022120	Identifikasi Bakteri Klebsiella Pneumonia Pada Penderita Isk di RSU Bunda Thamrin	4	Reisa Diah Salsabila	P07534022081	Pola Resistensi Antibiotik Terhadap Escherichia Coli Yang Diisolasi Dari Urin Penderita Isk di Laboratorium Bunda Thamrin	5	Novia Rahma bay	P07534022079	Identifikasi Bakteri Patogen Pada Pasien Penderita Infeksi Saluran Kemih Di Laboratorium Bunda Thamrin	6	Melisa Dermiyenti	P07534022122	Identifikasi Bakteri Escherichia Coli Pada Penderita Infeksi Saluran Kemih Di RSU Bunda Thamrin Medan
No	Nama	NIM	Judul Penelitian																											
1	Anugrah Napitupulu	P07534022055	Identifikasi Bakteri Staphylococcus Aureus Pada Penderita Infeksi Saluran Kemih Di RSU Bunda Thamrin Medan																											
2	Annisa Salsabila Siregar	P07534022054	Identifikasi Bakteri Proteus Mirabilis Pada Penderita Infeksi Saluran Kemih di RSU Bunda Thamrin Medan																											
3	Loveny Tamara Turnip	P07534022120	Identifikasi Bakteri Klebsiella Pneumonia Pada Penderita Isk di RSU Bunda Thamrin																											
4	Reisa Diah Salsabila	P07534022081	Pola Resistensi Antibiotik Terhadap Escherichia Coli Yang Diisolasi Dari Urin Penderita Isk di Laboratorium Bunda Thamrin																											
5	Novia Rahma bay	P07534022079	Identifikasi Bakteri Patogen Pada Pasien Penderita Infeksi Saluran Kemih Di Laboratorium Bunda Thamrin																											
6	Melisa Dermiyenti	P07534022122	Identifikasi Bakteri Escherichia Coli Pada Penderita Infeksi Saluran Kemih Di RSU Bunda Thamrin Medan																											

## LAMPIRAN 3

### ETHICAL CLEARENCE



Kementerian Kesehatan  
Poltekkes Medan  
Komisi Etik Penelitian Kesehatan  
Jalan Jamin Ginting KM. 13,5  
Medan, Sumatera Utara 20137  
(061) 8368633  
<https://poltekkes-medan.ac.id>

#### KETERANGAN LAYAK ETIK DESCRIPTION OF ETHICAL EXEMPTION "ETHICAL EXEMPTION"

No.01.26.1543/KEPK/POLTEKKES KEMENKES MEDAN 2025

Protokol penelitian versi 1 yang diusulkan oleh :  
*The research protocol proposed by*

Peneliti utama : Novia Rahma Bay  
*Principal Investigator*

Nama Institusi : Poltekkes Kemenkes Medan  
*Name of the Institution*

Dengan judul:  
*Title*  
**"IDENTIFIKASI BAKTERI PATOGEN PADA PASIEN PENDERITA INFEKSI SALURAN KEMIH (ISK) DI LABORATORIUM BUNDA THAMRIN TAHUN 2025"**

*"Identification of Pathogenic Bacteria in Patients with Urinary Tract Infections (UTIs) at Bunda Thamrin Laboratory in 2025"*

Dinyatakan layak etik sesuai 7 (tujuh) Standar WHO 2011, yaitu 1) Nilai Sosial, 2) Nilai Ilmiah, 3) Pemerataan Beban dan Manfaat, 4) Risiko, 5) Bujukan/Eksplorasi, 6) Kerahasiaan dan Privacy, dan 7) Persetujuan Setelah Penjelasan, yang merujuk pada Pedoman CIOMS 2016. Hal ini seperti yang ditunjukkan oleh terpenuhinya indikator setiap standar.

*Declared to be ethically appropriate in accordance to 7 (seven) WHO 2011 Standards, 1) Social Values, 2) Scientific Values, 3) Equitable Assessment and Benefits, 4) Risks, 5) Persuasion/Exploitation, 6) Confidentiality and Privacy, and 7) Informed Consent, referring to the 2016 CIOMS Guidelines. This is as indicated by the fulfillment of the indicators of each standard.*

Pernyataan Laik Etik ini berlaku selama kurun waktu tanggal 29 Juli 2025 sampai dengan tanggal 29 Juli 2026.

*This declaration of ethics applies during the period July 29, 2025 until July 29, 2026.*

*July 29, 2025  
Chairperson,*



Dr. Lestari Rahmah, MKT

00561/EE/2025/0159231271

**LAMPIRAN 4**  
**SURAT BALASAN PENELITIAN**



Medan, 13 Mei 2025

Nomor : 064/SU/DIR - LMBT/0525  
Hal : Balasan Surat Permohonan Izin Penelitian  
Lampiran : -

**Kepada Yth,**  
**Ketua Jurusan Teknologi Laboratorium Medis**  
**Poltekkes Medan**  
**di**  
**Tempat**

Dengan Hormat,  
Menindaklanjuti Surat Permohonan Izin Penelitian Nomor : KH.02.04/F/XXII.12/269/2025  
perihal permohonan izin penelitian kepada mahasiswa/i atas nama :

No	Nama	NIM
1	Novia Rahma Bay	P07534022079

Bersama ini kami sampaikan bahwa mahasiswa/i tersebut di atas dapat kami terima untuk melaksanakan Penelitian dan telah selesai melaksanakan penelitian di Laboratorium Medis Bunda Thamrin dalam memenuhi kewajiban/ menyelesaikan studi pada Poltekkes Medan, yang akan melakukan penelitian dengan judul : **Identifikasi Bakteri Patogen Pada Penderita Infeksi Saluran Kemih di Laboratorium Bunda Thamrin.** Demikian disampaikan, atas perhatiannya diucapkan terima kasih.

Hormat Kami,  
**Laboratorium Medis Bunda Thamrin**

  
**LABORATORIUM MEDIS**  
**BUNDA THAMRIN**  
Hendra Wibowo, S.E  
Direktur

# LAMPIRAN 5

## HASIL UJI PENELITIAN

Bionumber: 0405610554506650 Organism Quantity:		Selected Organism: <b>Escherichia coli</b>																																																																																																																																								
Comments:																																																																																																																																										
<b>McFarland:</b>																																																																																																																																										
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td><b>Identification Information</b></td> <td><b>Card:</b> GN</td> <td><b>Lot Number:</b> 2412813503</td> <td><b>Expires:</b> Aug 9, 2025 13:00 CDT</td> </tr> <tr> <td></td> <td><b>Status:</b> Final</td> <td><b>Analysis Time:</b> 6.87 hours</td> <td><b>Completed:</b> Apr 25, 2025 20:29 CDT</td> </tr> <tr> <td><b>Organism Origin</b></td> <td colspan="4">VITEK 2</td> </tr> <tr> <td><b>Selected Organism</b></td> <td colspan="4">97% Probability <b>Escherichia coli</b> Bionumber: 0405610554506650 Confidence: Very good identification</td> </tr> <tr> <td colspan="6"><b>Analysis Organism and Test to Separate:</b></td> </tr> <tr> <td colspan="6"><b>Analysis Messages:</b></td> </tr> <tr> <td colspan="6"><b>Constraining Typical Biopattern(s)</b> <b>Escherichia coli</b> AGAL(S), PHOS(B), LDC(B3)</td> </tr> <tr> <td colspan="6" style="border-top: none; border-bottom: 1px solid black; padding: 5px;"> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td><b>Susceptibility Information</b></td> <td><b>Card:</b> AST-GN93</td> <td><b>Lot Number:</b> 6833006103</td> <td><b>Expires:</b> Feb 18, 2026 12:00 CST</td> </tr> <tr> <td></td> <td><b>Status:</b> Final</td> <td><b>Analysis Time:</b> 8.58 hours</td> <td><b>Completed:</b> Apr 25, 2025 20:29 CDT</td> </tr> <tr> <td colspan="4"><b>McFarland:</b></td> </tr> <tr> <td colspan="4"> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> </tr> </thead> <tbody> <tr> <td>ESBL</td> <td>NEG</td> <td>-</td> <td>Cefipime</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>+Amoxicillin</td> <td>R</td> <td>Aztreonam</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>Ampicillin</td> <td>&gt;= 32</td> <td>Ertapenem</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>16</td> <td>Meropenem</td> <td>&lt;= 0.25</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>&lt;= 4</td> <td>Amikacin</td> <td>&lt;= 2</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td></td> <td>Gentamicin</td> <td>&gt;= 16</td> <td>R</td> </tr> <tr> <td>Urine</td> <td>&lt;= 4</td> <td>Ciprofloxacin</td> <td>&gt;= 4</td> <td>R</td> </tr> <tr> <td>Other</td> <td>&lt;= 4</td> <td>Tigecycline</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Cefazidime</td> <td>4</td> <td>Nitrofurantoin</td> <td>&lt;= 16</td> <td>S</td> </tr> <tr> <td>Ceftriaxone</td> <td>&lt;= 1</td> <td>Trimethoprim/ Sulfamethoxazole</td> <td>&gt;= 320</td> <td>R</td> </tr> </tbody> </table> </td> </tr> <tr> <td><b>AES Findings:</b></td> <td colspan="2">Last Modified: Oct 3, 2024 14:36 CDT</td> <td colspan="3">Parameter Set: Global CLSI 2024-based+Natural Resistance</td> </tr> <tr> <td>Confidence Level:</td> <td colspan="5">Consistent</td> </tr> </table> </td> </tr> <tr> <td colspan="6" style="border-top: none; border-bottom: 1px solid black; padding: 5px;"> <small>Installed VITEK 2 System Version 9.04.4 MIC Interpretation Guideline: Global CLSI 2024-based Therapeutic Interpretation Guideline: NATURAL RESISTANCE 2024</small> </td> </tr> </table>						<b>Identification Information</b>	<b>Card:</b> GN	<b>Lot Number:</b> 2412813503	<b>Expires:</b> Aug 9, 2025 13:00 CDT		<b>Status:</b> Final	<b>Analysis Time:</b> 6.87 hours	<b>Completed:</b> Apr 25, 2025 20:29 CDT	<b>Organism Origin</b>	VITEK 2				<b>Selected Organism</b>	97% Probability <b>Escherichia coli</b> Bionumber: 0405610554506650 Confidence: Very good identification				<b>Analysis Organism and Test to Separate:</b>						<b>Analysis Messages:</b>						<b>Constraining Typical Biopattern(s)</b> <b>Escherichia coli</b> AGAL(S), PHOS(B), LDC(B3)						<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td><b>Susceptibility Information</b></td> <td><b>Card:</b> AST-GN93</td> <td><b>Lot Number:</b> 6833006103</td> <td><b>Expires:</b> Feb 18, 2026 12:00 CST</td> </tr> <tr> <td></td> <td><b>Status:</b> Final</td> <td><b>Analysis Time:</b> 8.58 hours</td> <td><b>Completed:</b> Apr 25, 2025 20:29 CDT</td> </tr> <tr> <td colspan="4"><b>McFarland:</b></td> </tr> <tr> <td colspan="4"> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> </tr> </thead> <tbody> <tr> <td>ESBL</td> <td>NEG</td> <td>-</td> <td>Cefipime</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>+Amoxicillin</td> <td>R</td> <td>Aztreonam</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>Ampicillin</td> <td>&gt;= 32</td> <td>Ertapenem</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>16</td> <td>Meropenem</td> <td>&lt;= 0.25</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>&lt;= 4</td> <td>Amikacin</td> <td>&lt;= 2</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td></td> <td>Gentamicin</td> <td>&gt;= 16</td> <td>R</td> </tr> <tr> <td>Urine</td> <td>&lt;= 4</td> <td>Ciprofloxacin</td> <td>&gt;= 4</td> <td>R</td> </tr> <tr> <td>Other</td> <td>&lt;= 4</td> <td>Tigecycline</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Cefazidime</td> <td>4</td> <td>Nitrofurantoin</td> <td>&lt;= 16</td> <td>S</td> </tr> <tr> <td>Ceftriaxone</td> <td>&lt;= 1</td> <td>Trimethoprim/ Sulfamethoxazole</td> <td>&gt;= 320</td> <td>R</td> </tr> </tbody> </table> </td> </tr> <tr> <td><b>AES Findings:</b></td> <td colspan="2">Last Modified: Oct 3, 2024 14:36 CDT</td> <td colspan="3">Parameter Set: Global CLSI 2024-based+Natural Resistance</td> </tr> <tr> <td>Confidence Level:</td> <td colspan="5">Consistent</td> </tr> </table>						<b>Susceptibility Information</b>	<b>Card:</b> AST-GN93	<b>Lot Number:</b> 6833006103	<b>Expires:</b> Feb 18, 2026 12:00 CST		<b>Status:</b> Final	<b>Analysis Time:</b> 8.58 hours	<b>Completed:</b> Apr 25, 2025 20:29 CDT	<b>McFarland:</b>				<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> </tr> </thead> <tbody> <tr> <td>ESBL</td> <td>NEG</td> <td>-</td> <td>Cefipime</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>+Amoxicillin</td> <td>R</td> <td>Aztreonam</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>Ampicillin</td> <td>&gt;= 32</td> <td>Ertapenem</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>16</td> <td>Meropenem</td> <td>&lt;= 0.25</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>&lt;= 4</td> <td>Amikacin</td> <td>&lt;= 2</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td></td> <td>Gentamicin</td> <td>&gt;= 16</td> <td>R</td> </tr> <tr> <td>Urine</td> <td>&lt;= 4</td> <td>Ciprofloxacin</td> <td>&gt;= 4</td> <td>R</td> </tr> <tr> <td>Other</td> <td>&lt;= 4</td> <td>Tigecycline</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Cefazidime</td> <td>4</td> <td>Nitrofurantoin</td> <td>&lt;= 16</td> <td>S</td> </tr> <tr> <td>Ceftriaxone</td> <td>&lt;= 1</td> <td>Trimethoprim/ Sulfamethoxazole</td> <td>&gt;= 320</td> <td>R</td> </tr> </tbody> </table>				<b>Antimicrobial</b>	<b>MIC</b>	<b>Interpretation</b>	<b>Antimicrobial</b>	<b>MIC</b>	<b>Interpretation</b>	ESBL	NEG	-	Cefipime	<= 1	S	+Amoxicillin	R	Aztreonam	<= 1	S	Ampicillin	>= 32	Ertapenem	<= 0.5	S	Ampicillin/Sulbactam	16	Meropenem	<= 0.25	S	Piperacillin/Tazobactam	<= 4	Amikacin	<= 2	S	Cefazolin		Gentamicin	>= 16	R	Urine	<= 4	Ciprofloxacin	>= 4	R	Other	<= 4	Tigecycline	<= 0.5	S	Cefazidime	4	Nitrofurantoin	<= 16	S	Ceftriaxone	<= 1	Trimethoprim/ Sulfamethoxazole	>= 320	R	<b>AES Findings:</b>	Last Modified: Oct 3, 2024 14:36 CDT		Parameter Set: Global CLSI 2024-based+Natural Resistance			Confidence Level:	Consistent					<small>Installed VITEK 2 System Version 9.04.4 MIC Interpretation Guideline: Global CLSI 2024-based Therapeutic Interpretation Guideline: NATURAL RESISTANCE 2024</small>					
<b>Identification Information</b>	<b>Card:</b> GN	<b>Lot Number:</b> 2412813503	<b>Expires:</b> Aug 9, 2025 13:00 CDT																																																																																																																																							
	<b>Status:</b> Final	<b>Analysis Time:</b> 6.87 hours	<b>Completed:</b> Apr 25, 2025 20:29 CDT																																																																																																																																							
<b>Organism Origin</b>	VITEK 2																																																																																																																																									
<b>Selected Organism</b>	97% Probability <b>Escherichia coli</b> Bionumber: 0405610554506650 Confidence: Very good identification																																																																																																																																									
<b>Analysis Organism and Test to Separate:</b>																																																																																																																																										
<b>Analysis Messages:</b>																																																																																																																																										
<b>Constraining Typical Biopattern(s)</b> <b>Escherichia coli</b> AGAL(S), PHOS(B), LDC(B3)																																																																																																																																										
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td><b>Susceptibility Information</b></td> <td><b>Card:</b> AST-GN93</td> <td><b>Lot Number:</b> 6833006103</td> <td><b>Expires:</b> Feb 18, 2026 12:00 CST</td> </tr> <tr> <td></td> <td><b>Status:</b> Final</td> <td><b>Analysis Time:</b> 8.58 hours</td> <td><b>Completed:</b> Apr 25, 2025 20:29 CDT</td> </tr> <tr> <td colspan="4"><b>McFarland:</b></td> </tr> <tr> <td colspan="4"> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> </tr> </thead> <tbody> <tr> <td>ESBL</td> <td>NEG</td> <td>-</td> <td>Cefipime</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>+Amoxicillin</td> <td>R</td> <td>Aztreonam</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>Ampicillin</td> <td>&gt;= 32</td> <td>Ertapenem</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>16</td> <td>Meropenem</td> <td>&lt;= 0.25</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>&lt;= 4</td> <td>Amikacin</td> <td>&lt;= 2</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td></td> <td>Gentamicin</td> <td>&gt;= 16</td> <td>R</td> </tr> <tr> <td>Urine</td> <td>&lt;= 4</td> <td>Ciprofloxacin</td> <td>&gt;= 4</td> <td>R</td> </tr> <tr> <td>Other</td> <td>&lt;= 4</td> <td>Tigecycline</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Cefazidime</td> <td>4</td> <td>Nitrofurantoin</td> <td>&lt;= 16</td> <td>S</td> </tr> <tr> <td>Ceftriaxone</td> <td>&lt;= 1</td> <td>Trimethoprim/ Sulfamethoxazole</td> <td>&gt;= 320</td> <td>R</td> </tr> </tbody> </table> </td> </tr> <tr> <td><b>AES Findings:</b></td> <td colspan="2">Last Modified: Oct 3, 2024 14:36 CDT</td> <td colspan="3">Parameter Set: Global CLSI 2024-based+Natural Resistance</td> </tr> <tr> <td>Confidence Level:</td> <td colspan="5">Consistent</td> </tr> </table>						<b>Susceptibility Information</b>	<b>Card:</b> AST-GN93	<b>Lot Number:</b> 6833006103	<b>Expires:</b> Feb 18, 2026 12:00 CST		<b>Status:</b> Final	<b>Analysis Time:</b> 8.58 hours	<b>Completed:</b> Apr 25, 2025 20:29 CDT	<b>McFarland:</b>				<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> </tr> </thead> <tbody> <tr> <td>ESBL</td> <td>NEG</td> <td>-</td> <td>Cefipime</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>+Amoxicillin</td> <td>R</td> <td>Aztreonam</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>Ampicillin</td> <td>&gt;= 32</td> <td>Ertapenem</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>16</td> <td>Meropenem</td> <td>&lt;= 0.25</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>&lt;= 4</td> <td>Amikacin</td> <td>&lt;= 2</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td></td> <td>Gentamicin</td> <td>&gt;= 16</td> <td>R</td> </tr> <tr> <td>Urine</td> <td>&lt;= 4</td> <td>Ciprofloxacin</td> <td>&gt;= 4</td> <td>R</td> </tr> <tr> <td>Other</td> <td>&lt;= 4</td> <td>Tigecycline</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Cefazidime</td> <td>4</td> <td>Nitrofurantoin</td> <td>&lt;= 16</td> <td>S</td> </tr> <tr> <td>Ceftriaxone</td> <td>&lt;= 1</td> <td>Trimethoprim/ Sulfamethoxazole</td> <td>&gt;= 320</td> <td>R</td> </tr> </tbody> </table>				<b>Antimicrobial</b>	<b>MIC</b>	<b>Interpretation</b>	<b>Antimicrobial</b>	<b>MIC</b>	<b>Interpretation</b>	ESBL	NEG	-	Cefipime	<= 1	S	+Amoxicillin	R	Aztreonam	<= 1	S	Ampicillin	>= 32	Ertapenem	<= 0.5	S	Ampicillin/Sulbactam	16	Meropenem	<= 0.25	S	Piperacillin/Tazobactam	<= 4	Amikacin	<= 2	S	Cefazolin		Gentamicin	>= 16	R	Urine	<= 4	Ciprofloxacin	>= 4	R	Other	<= 4	Tigecycline	<= 0.5	S	Cefazidime	4	Nitrofurantoin	<= 16	S	Ceftriaxone	<= 1	Trimethoprim/ Sulfamethoxazole	>= 320	R	<b>AES Findings:</b>	Last Modified: Oct 3, 2024 14:36 CDT		Parameter Set: Global CLSI 2024-based+Natural Resistance			Confidence Level:	Consistent																																																				
<b>Susceptibility Information</b>	<b>Card:</b> AST-GN93	<b>Lot Number:</b> 6833006103	<b>Expires:</b> Feb 18, 2026 12:00 CST																																																																																																																																							
	<b>Status:</b> Final	<b>Analysis Time:</b> 8.58 hours	<b>Completed:</b> Apr 25, 2025 20:29 CDT																																																																																																																																							
<b>McFarland:</b>																																																																																																																																										
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> </tr> </thead> <tbody> <tr> <td>ESBL</td> <td>NEG</td> <td>-</td> <td>Cefipime</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>+Amoxicillin</td> <td>R</td> <td>Aztreonam</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>Ampicillin</td> <td>&gt;= 32</td> <td>Ertapenem</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>16</td> <td>Meropenem</td> <td>&lt;= 0.25</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>&lt;= 4</td> <td>Amikacin</td> <td>&lt;= 2</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td></td> <td>Gentamicin</td> <td>&gt;= 16</td> <td>R</td> </tr> <tr> <td>Urine</td> <td>&lt;= 4</td> <td>Ciprofloxacin</td> <td>&gt;= 4</td> <td>R</td> </tr> <tr> <td>Other</td> <td>&lt;= 4</td> <td>Tigecycline</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Cefazidime</td> <td>4</td> <td>Nitrofurantoin</td> <td>&lt;= 16</td> <td>S</td> </tr> <tr> <td>Ceftriaxone</td> <td>&lt;= 1</td> <td>Trimethoprim/ Sulfamethoxazole</td> <td>&gt;= 320</td> <td>R</td> </tr> </tbody> </table>				<b>Antimicrobial</b>	<b>MIC</b>	<b>Interpretation</b>	<b>Antimicrobial</b>	<b>MIC</b>	<b>Interpretation</b>	ESBL	NEG	-	Cefipime	<= 1	S	+Amoxicillin	R	Aztreonam	<= 1	S	Ampicillin	>= 32	Ertapenem	<= 0.5	S	Ampicillin/Sulbactam	16	Meropenem	<= 0.25	S	Piperacillin/Tazobactam	<= 4	Amikacin	<= 2	S	Cefazolin		Gentamicin	>= 16	R	Urine	<= 4	Ciprofloxacin	>= 4	R	Other	<= 4	Tigecycline	<= 0.5	S	Cefazidime	4	Nitrofurantoin	<= 16	S	Ceftriaxone	<= 1	Trimethoprim/ Sulfamethoxazole	>= 320	R																																																																														
<b>Antimicrobial</b>	<b>MIC</b>	<b>Interpretation</b>	<b>Antimicrobial</b>	<b>MIC</b>	<b>Interpretation</b>																																																																																																																																					
ESBL	NEG	-	Cefipime	<= 1	S																																																																																																																																					
+Amoxicillin	R	Aztreonam	<= 1	S																																																																																																																																						
Ampicillin	>= 32	Ertapenem	<= 0.5	S																																																																																																																																						
Ampicillin/Sulbactam	16	Meropenem	<= 0.25	S																																																																																																																																						
Piperacillin/Tazobactam	<= 4	Amikacin	<= 2	S																																																																																																																																						
Cefazolin		Gentamicin	>= 16	R																																																																																																																																						
Urine	<= 4	Ciprofloxacin	>= 4	R																																																																																																																																						
Other	<= 4	Tigecycline	<= 0.5	S																																																																																																																																						
Cefazidime	4	Nitrofurantoin	<= 16	S																																																																																																																																						
Ceftriaxone	<= 1	Trimethoprim/ Sulfamethoxazole	>= 320	R																																																																																																																																						
<b>AES Findings:</b>	Last Modified: Oct 3, 2024 14:36 CDT		Parameter Set: Global CLSI 2024-based+Natural Resistance																																																																																																																																							
Confidence Level:	Consistent																																																																																																																																									
<small>Installed VITEK 2 System Version 9.04.4 MIC Interpretation Guideline: Global CLSI 2024-based Therapeutic Interpretation Guideline: NATURAL RESISTANCE 2024</small>																																																																																																																																										

Bionumber: 2405610544524610 Organism Quantity:		Selected Organism: <b>Escherichia coli</b>																																																																																																																																								
Comments:																																																																																																																																										
<b>McFarland:</b>																																																																																																																																										
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td><b>Identification Information</b></td> <td><b>Card:</b> GN</td> <td><b>Lot Number:</b> 2412813503</td> <td><b>Expires:</b> Aug 9, 2025 13:00 CDT</td> </tr> <tr> <td></td> <td><b>Status:</b> Final</td> <td><b>Analysis Time:</b> 3.90 hours</td> <td><b>Completed:</b> Mei 7, 2025 15:10 CDT</td> </tr> <tr> <td><b>Organism Origin</b></td> <td colspan="4">VITEK 2</td> </tr> <tr> <td><b>Selected Organism</b></td> <td colspan="4">97% Probability <b>Escherichia coli</b> Bionumber: 2405610544524610 Confidence: Excellent identification</td> </tr> <tr> <td colspan="6"><b>Analysis Organism and Test to Separate:</b></td> </tr> <tr> <td colspan="6"><b>Analysis Messages:</b></td> </tr> <tr> <td colspan="6"><b>Constraining Typical Biopattern(s)</b> <b>Escherichia coli</b> ADO(9)</td> </tr> <tr> <td colspan="6" style="border-top: none; border-bottom: 1px solid black; padding: 5px;"> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td><b>Susceptibility Information</b></td> <td><b>Card:</b> AST-GN93</td> <td><b>Lot Number:</b> 6833006103</td> <td><b>Expires:</b> Feb 18, 2026 12:00 CST</td> </tr> <tr> <td></td> <td><b>Status:</b> Final</td> <td><b>Analysis Time:</b> 8.28 hours</td> <td><b>Completed:</b> Mei 7, 2025 19:33 CDT</td> </tr> <tr> <td colspan="4"><b>McFarland:</b></td> </tr> <tr> <td colspan="4"> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> </tr> </thead> <tbody> <tr> <td>ESBL</td> <td>POS</td> <td>+</td> <td>Cefipime</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>+Amoxicillin</td> <td>R</td> <td>Aztreonam</td> <td>16</td> <td>R</td> </tr> <tr> <td>Ampicillin</td> <td>&gt;= 32</td> <td>Ertapenem</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>&gt;= 32</td> <td>Meropenem</td> <td>&lt;= 0.25</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>&lt;= 4</td> <td>Amikacin</td> <td>&lt;= 2</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td></td> <td>Gentamicin</td> <td>&gt;= 16</td> <td>R</td> </tr> <tr> <td>Urine</td> <td>&gt;= 64</td> <td>Ciprofloxacin</td> <td>1</td> <td>R</td> </tr> <tr> <td>Other</td> <td>&gt;= 64</td> <td>Tigecycline</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Cefazidime</td> <td>16</td> <td>Nitrofurantoin</td> <td>&lt;= 16</td> <td>S</td> </tr> <tr> <td>Ceftriaxone</td> <td>&gt;= 64</td> <td>Trimethoprim/ Sulfamethoxazole</td> <td>&gt;= 320</td> <td>R</td> </tr> </tbody> </table> </td> </tr> <tr> <td><b>AES Findings:</b></td> <td colspan="2">Last Modified: Oct 3, 2024 14:36 CDT</td> <td colspan="3">Parameter Set: Global CLSI 2024-based+Natural Resistance</td> </tr> <tr> <td>Confidence Level:</td> <td colspan="5">Consistent</td> </tr> </table> </td> </tr> <tr> <td colspan="6" style="border-top: none; border-bottom: 1px solid black; padding: 5px;"> <small>Installed VITEK 2 System Version 9.04.4 MIC Interpretation Guideline: Global CLSI 2024-based Therapeutic Interpretation Guideline: NATURAL RESISTANCE 2024</small> </td> </tr> </table>						<b>Identification Information</b>	<b>Card:</b> GN	<b>Lot Number:</b> 2412813503	<b>Expires:</b> Aug 9, 2025 13:00 CDT		<b>Status:</b> Final	<b>Analysis Time:</b> 3.90 hours	<b>Completed:</b> Mei 7, 2025 15:10 CDT	<b>Organism Origin</b>	VITEK 2				<b>Selected Organism</b>	97% Probability <b>Escherichia coli</b> Bionumber: 2405610544524610 Confidence: Excellent identification				<b>Analysis Organism and Test to Separate:</b>						<b>Analysis Messages:</b>						<b>Constraining Typical Biopattern(s)</b> <b>Escherichia coli</b> ADO(9)						<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td><b>Susceptibility Information</b></td> <td><b>Card:</b> AST-GN93</td> <td><b>Lot Number:</b> 6833006103</td> <td><b>Expires:</b> Feb 18, 2026 12:00 CST</td> </tr> <tr> <td></td> <td><b>Status:</b> Final</td> <td><b>Analysis Time:</b> 8.28 hours</td> <td><b>Completed:</b> Mei 7, 2025 19:33 CDT</td> </tr> <tr> <td colspan="4"><b>McFarland:</b></td> </tr> <tr> <td colspan="4"> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> </tr> </thead> <tbody> <tr> <td>ESBL</td> <td>POS</td> <td>+</td> <td>Cefipime</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>+Amoxicillin</td> <td>R</td> <td>Aztreonam</td> <td>16</td> <td>R</td> </tr> <tr> <td>Ampicillin</td> <td>&gt;= 32</td> <td>Ertapenem</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>&gt;= 32</td> <td>Meropenem</td> <td>&lt;= 0.25</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>&lt;= 4</td> <td>Amikacin</td> <td>&lt;= 2</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td></td> <td>Gentamicin</td> <td>&gt;= 16</td> <td>R</td> </tr> <tr> <td>Urine</td> <td>&gt;= 64</td> <td>Ciprofloxacin</td> <td>1</td> <td>R</td> </tr> <tr> <td>Other</td> <td>&gt;= 64</td> <td>Tigecycline</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Cefazidime</td> <td>16</td> <td>Nitrofurantoin</td> <td>&lt;= 16</td> <td>S</td> </tr> <tr> <td>Ceftriaxone</td> <td>&gt;= 64</td> <td>Trimethoprim/ Sulfamethoxazole</td> <td>&gt;= 320</td> <td>R</td> </tr> </tbody> </table> </td> </tr> <tr> <td><b>AES Findings:</b></td> <td colspan="2">Last Modified: Oct 3, 2024 14:36 CDT</td> <td colspan="3">Parameter Set: Global CLSI 2024-based+Natural Resistance</td> </tr> <tr> <td>Confidence Level:</td> <td colspan="5">Consistent</td> </tr> </table>						<b>Susceptibility Information</b>	<b>Card:</b> AST-GN93	<b>Lot Number:</b> 6833006103	<b>Expires:</b> Feb 18, 2026 12:00 CST		<b>Status:</b> Final	<b>Analysis Time:</b> 8.28 hours	<b>Completed:</b> Mei 7, 2025 19:33 CDT	<b>McFarland:</b>				<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> </tr> </thead> <tbody> <tr> <td>ESBL</td> <td>POS</td> <td>+</td> <td>Cefipime</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>+Amoxicillin</td> <td>R</td> <td>Aztreonam</td> <td>16</td> <td>R</td> </tr> <tr> <td>Ampicillin</td> <td>&gt;= 32</td> <td>Ertapenem</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>&gt;= 32</td> <td>Meropenem</td> <td>&lt;= 0.25</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>&lt;= 4</td> <td>Amikacin</td> <td>&lt;= 2</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td></td> <td>Gentamicin</td> <td>&gt;= 16</td> <td>R</td> </tr> <tr> <td>Urine</td> <td>&gt;= 64</td> <td>Ciprofloxacin</td> <td>1</td> <td>R</td> </tr> <tr> <td>Other</td> <td>&gt;= 64</td> <td>Tigecycline</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Cefazidime</td> <td>16</td> <td>Nitrofurantoin</td> <td>&lt;= 16</td> <td>S</td> </tr> <tr> <td>Ceftriaxone</td> <td>&gt;= 64</td> <td>Trimethoprim/ Sulfamethoxazole</td> <td>&gt;= 320</td> <td>R</td> </tr> </tbody> </table>				<b>Antimicrobial</b>	<b>MIC</b>	<b>Interpretation</b>	<b>Antimicrobial</b>	<b>MIC</b>	<b>Interpretation</b>	ESBL	POS	+	Cefipime	<= 1	S	+Amoxicillin	R	Aztreonam	16	R	Ampicillin	>= 32	Ertapenem	<= 0.5	S	Ampicillin/Sulbactam	>= 32	Meropenem	<= 0.25	S	Piperacillin/Tazobactam	<= 4	Amikacin	<= 2	S	Cefazolin		Gentamicin	>= 16	R	Urine	>= 64	Ciprofloxacin	1	R	Other	>= 64	Tigecycline	<= 0.5	S	Cefazidime	16	Nitrofurantoin	<= 16	S	Ceftriaxone	>= 64	Trimethoprim/ Sulfamethoxazole	>= 320	R	<b>AES Findings:</b>	Last Modified: Oct 3, 2024 14:36 CDT		Parameter Set: Global CLSI 2024-based+Natural Resistance			Confidence Level:	Consistent					<small>Installed VITEK 2 System Version 9.04.4 MIC Interpretation Guideline: Global CLSI 2024-based Therapeutic Interpretation Guideline: NATURAL RESISTANCE 2024</small>					
<b>Identification Information</b>	<b>Card:</b> GN	<b>Lot Number:</b> 2412813503	<b>Expires:</b> Aug 9, 2025 13:00 CDT																																																																																																																																							
	<b>Status:</b> Final	<b>Analysis Time:</b> 3.90 hours	<b>Completed:</b> Mei 7, 2025 15:10 CDT																																																																																																																																							
<b>Organism Origin</b>	VITEK 2																																																																																																																																									
<b>Selected Organism</b>	97% Probability <b>Escherichia coli</b> Bionumber: 2405610544524610 Confidence: Excellent identification																																																																																																																																									
<b>Analysis Organism and Test to Separate:</b>																																																																																																																																										
<b>Analysis Messages:</b>																																																																																																																																										
<b>Constraining Typical Biopattern(s)</b> <b>Escherichia coli</b> ADO(9)																																																																																																																																										
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td><b>Susceptibility Information</b></td> <td><b>Card:</b> AST-GN93</td> <td><b>Lot Number:</b> 6833006103</td> <td><b>Expires:</b> Feb 18, 2026 12:00 CST</td> </tr> <tr> <td></td> <td><b>Status:</b> Final</td> <td><b>Analysis Time:</b> 8.28 hours</td> <td><b>Completed:</b> Mei 7, 2025 19:33 CDT</td> </tr> <tr> <td colspan="4"><b>McFarland:</b></td> </tr> <tr> <td colspan="4"> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> </tr> </thead> <tbody> <tr> <td>ESBL</td> <td>POS</td> <td>+</td> <td>Cefipime</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>+Amoxicillin</td> <td>R</td> <td>Aztreonam</td> <td>16</td> <td>R</td> </tr> <tr> <td>Ampicillin</td> <td>&gt;= 32</td> <td>Ertapenem</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>&gt;= 32</td> <td>Meropenem</td> <td>&lt;= 0.25</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>&lt;= 4</td> <td>Amikacin</td> <td>&lt;= 2</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td></td> <td>Gentamicin</td> <td>&gt;= 16</td> <td>R</td> </tr> <tr> <td>Urine</td> <td>&gt;= 64</td> <td>Ciprofloxacin</td> <td>1</td> <td>R</td> </tr> <tr> <td>Other</td> <td>&gt;= 64</td> <td>Tigecycline</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Cefazidime</td> <td>16</td> <td>Nitrofurantoin</td> <td>&lt;= 16</td> <td>S</td> </tr> <tr> <td>Ceftriaxone</td> <td>&gt;= 64</td> <td>Trimethoprim/ Sulfamethoxazole</td> <td>&gt;= 320</td> <td>R</td> </tr> </tbody> </table> </td> </tr> <tr> <td><b>AES Findings:</b></td> <td colspan="2">Last Modified: Oct 3, 2024 14:36 CDT</td> <td colspan="3">Parameter Set: Global CLSI 2024-based+Natural Resistance</td> </tr> <tr> <td>Confidence Level:</td> <td colspan="5">Consistent</td> </tr> </table>						<b>Susceptibility Information</b>	<b>Card:</b> AST-GN93	<b>Lot Number:</b> 6833006103	<b>Expires:</b> Feb 18, 2026 12:00 CST		<b>Status:</b> Final	<b>Analysis Time:</b> 8.28 hours	<b>Completed:</b> Mei 7, 2025 19:33 CDT	<b>McFarland:</b>				<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> </tr> </thead> <tbody> <tr> <td>ESBL</td> <td>POS</td> <td>+</td> <td>Cefipime</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>+Amoxicillin</td> <td>R</td> <td>Aztreonam</td> <td>16</td> <td>R</td> </tr> <tr> <td>Ampicillin</td> <td>&gt;= 32</td> <td>Ertapenem</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>&gt;= 32</td> <td>Meropenem</td> <td>&lt;= 0.25</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>&lt;= 4</td> <td>Amikacin</td> <td>&lt;= 2</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td></td> <td>Gentamicin</td> <td>&gt;= 16</td> <td>R</td> </tr> <tr> <td>Urine</td> <td>&gt;= 64</td> <td>Ciprofloxacin</td> <td>1</td> <td>R</td> </tr> <tr> <td>Other</td> <td>&gt;= 64</td> <td>Tigecycline</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Cefazidime</td> <td>16</td> <td>Nitrofurantoin</td> <td>&lt;= 16</td> <td>S</td> </tr> <tr> <td>Ceftriaxone</td> <td>&gt;= 64</td> <td>Trimethoprim/ Sulfamethoxazole</td> <td>&gt;= 320</td> <td>R</td> </tr> </tbody> </table>				<b>Antimicrobial</b>	<b>MIC</b>	<b>Interpretation</b>	<b>Antimicrobial</b>	<b>MIC</b>	<b>Interpretation</b>	ESBL	POS	+	Cefipime	<= 1	S	+Amoxicillin	R	Aztreonam	16	R	Ampicillin	>= 32	Ertapenem	<= 0.5	S	Ampicillin/Sulbactam	>= 32	Meropenem	<= 0.25	S	Piperacillin/Tazobactam	<= 4	Amikacin	<= 2	S	Cefazolin		Gentamicin	>= 16	R	Urine	>= 64	Ciprofloxacin	1	R	Other	>= 64	Tigecycline	<= 0.5	S	Cefazidime	16	Nitrofurantoin	<= 16	S	Ceftriaxone	>= 64	Trimethoprim/ Sulfamethoxazole	>= 320	R	<b>AES Findings:</b>	Last Modified: Oct 3, 2024 14:36 CDT		Parameter Set: Global CLSI 2024-based+Natural Resistance			Confidence Level:	Consistent																																																				
<b>Susceptibility Information</b>	<b>Card:</b> AST-GN93	<b>Lot Number:</b> 6833006103	<b>Expires:</b> Feb 18, 2026 12:00 CST																																																																																																																																							
	<b>Status:</b> Final	<b>Analysis Time:</b> 8.28 hours	<b>Completed:</b> Mei 7, 2025 19:33 CDT																																																																																																																																							
<b>McFarland:</b>																																																																																																																																										
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> <th><b>Antimicrobial</b></th> <th><b>MIC</b></th> <th><b>Interpretation</b></th> </tr> </thead> <tbody> <tr> <td>ESBL</td> <td>POS</td> <td>+</td> <td>Cefipime</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>+Amoxicillin</td> <td>R</td> <td>Aztreonam</td> <td>16</td> <td>R</td> </tr> <tr> <td>Ampicillin</td> <td>&gt;= 32</td> <td>Ertapenem</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>&gt;= 32</td> <td>Meropenem</td> <td>&lt;= 0.25</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>&lt;= 4</td> <td>Amikacin</td> <td>&lt;= 2</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td></td> <td>Gentamicin</td> <td>&gt;= 16</td> <td>R</td> </tr> <tr> <td>Urine</td> <td>&gt;= 64</td> <td>Ciprofloxacin</td> <td>1</td> <td>R</td> </tr> <tr> <td>Other</td> <td>&gt;= 64</td> <td>Tigecycline</td> <td>&lt;= 0.5</td> <td>S</td> </tr> <tr> <td>Cefazidime</td> <td>16</td> <td>Nitrofurantoin</td> <td>&lt;= 16</td> <td>S</td> </tr> <tr> <td>Ceftriaxone</td> <td>&gt;= 64</td> <td>Trimethoprim/ Sulfamethoxazole</td> <td>&gt;= 320</td> <td>R</td> </tr> </tbody> </table>				<b>Antimicrobial</b>	<b>MIC</b>	<b>Interpretation</b>	<b>Antimicrobial</b>	<b>MIC</b>	<b>Interpretation</b>	ESBL	POS	+	Cefipime	<= 1	S	+Amoxicillin	R	Aztreonam	16	R	Ampicillin	>= 32	Ertapenem	<= 0.5	S	Ampicillin/Sulbactam	>= 32	Meropenem	<= 0.25	S	Piperacillin/Tazobactam	<= 4	Amikacin	<= 2	S	Cefazolin		Gentamicin	>= 16	R	Urine	>= 64	Ciprofloxacin	1	R	Other	>= 64	Tigecycline	<= 0.5	S	Cefazidime	16	Nitrofurantoin	<= 16	S	Ceftriaxone	>= 64	Trimethoprim/ Sulfamethoxazole	>= 320	R																																																																														
<b>Antimicrobial</b>	<b>MIC</b>	<b>Interpretation</b>	<b>Antimicrobial</b>	<b>MIC</b>	<b>Interpretation</b>																																																																																																																																					
ESBL	POS	+	Cefipime	<= 1	S																																																																																																																																					
+Amoxicillin	R	Aztreonam	16	R																																																																																																																																						
Ampicillin	>= 32	Ertapenem	<= 0.5	S																																																																																																																																						
Ampicillin/Sulbactam	>= 32	Meropenem	<= 0.25	S																																																																																																																																						
Piperacillin/Tazobactam	<= 4	Amikacin	<= 2	S																																																																																																																																						
Cefazolin		Gentamicin	>= 16	R																																																																																																																																						
Urine	>= 64	Ciprofloxacin	1	R																																																																																																																																						
Other	>= 64	Tigecycline	<= 0.5	S																																																																																																																																						
Cefazidime	16	Nitrofurantoin	<= 16	S																																																																																																																																						
Ceftriaxone	>= 64	Trimethoprim/ Sulfamethoxazole	>= 320	R																																																																																																																																						
<b>AES Findings:</b>	Last Modified: Oct 3, 2024 14:36 CDT		Parameter Set: Global CLSI 2024-based+Natural Resistance																																																																																																																																							
Confidence Level:	Consistent																																																																																																																																									
<small>Installed VITEK 2 System Version 9.04.4 MIC Interpretation Guideline: Global CLSI 2024-based Therapeutic Interpretation Guideline: NATURAL RESISTANCE 2024</small>																																																																																																																																										

<p>Selected Organism: Acinetobacter baumannii</p> <p>Comments:</p>																																																							
<p><b>McFarland</b></p> <p><b>Identification Information</b> Card: GN Status: Final Analysis Time: 5:78 hours Complet.: Mar 31, 2025 17:11 CDT Organism Origin: VITEK 2 Selected Organism: OXA-Producing Acinetobacter baumannii Biomarker: 024-00115502-0 Organism Quantity: Comments:</p>																																																							
<p><b>Identification Information</b> Card: GN Lot Number: 2212813803 Exp.: 2 Aug 9, 2025 13:00 CST Status: Final Analysis Time: 5:78 hours Complet.: Mar 31, 2025 17:11 CDT Organism Origin: VITEK 2 Selected Organism: OXA-Producing Acinetobacter baumannii Biomarker: 024-00115502-0 Confidence: &gt; 95% identification Analysis Organisms and Tests in Separation: Acinetobacter baumannii Acinetobacter baumannii Analysis Messages: The following antibiotic(s) are inactive: ESBLs Contradicting/Typical Biopotency(s):</p>																																																							
<p><b>McFarland</b></p> <p><b>Susceptibility Information</b> Card: AST-C93 Status: Final Analysis Time: 7:81 hours Complet.: Mar 31, 2025 19:23 CDT <table border="1"> <thead> <tr> <th>Antimicrobial</th> <th>MIC</th> <th>Interpretation</th> <th>Antimicrobial</th> <th>MIC</th> <th>Interpretation</th> </tr> </thead> <tbody> <tr> <td>ESBL</td> <td>-</td> <td>Inactive</td> <td>Ampicillin</td> <td>&gt;= 16</td> <td>R</td> </tr> <tr> <td>Ampicillin</td> <td>1</td> <td>Intermediate</td> <td>Ampicillin</td> <td>&gt;= 64</td> <td>R</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>16</td> <td>Intermediate</td> <td>Piperacillin/Tazobactam</td> <td>&gt;= 16</td> <td>R</td> </tr> <tr> <td>Cefazolin</td> <td>128</td> <td>Resistant</td> <td>Ceftazidime</td> <td>&gt;= 4</td> <td>R</td> </tr> <tr> <td>Ceftazidime</td> <td>32</td> <td>Resistant</td> <td>Ceftriaxone</td> <td>4</td> <td>I</td> </tr> <tr> <td>Ceftriaxone</td> <td>64</td> <td>Resistant</td> <td>Cefepime</td> <td>&gt;= 512</td> <td>R</td> </tr> <tr> <td>Cefepime</td> <td>64</td> <td>Resistant</td> <td>Ciprofloxacin</td> <td>&gt;= 320</td> <td>R</td> </tr> <tr> <td>Aztreonam</td> <td>-</td> <td>-</td> <td></td> <td></td> <td></td> </tr> </tbody> </table> <p><b>AES Finding:</b> Last Modified: Oct 3, 2024 14:36 CDT Parameter Set: Global CLSI 2024-based (Natural Resistance) Confidence Level: Consistent</p> </p>		Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	Interpretation	ESBL	-	Inactive	Ampicillin	>= 16	R	Ampicillin	1	Intermediate	Ampicillin	>= 64	R	Ampicillin/Sulbactam	16	Intermediate	Piperacillin/Tazobactam	>= 16	R	Cefazolin	128	Resistant	Ceftazidime	>= 4	R	Ceftazidime	32	Resistant	Ceftriaxone	4	I	Ceftriaxone	64	Resistant	Cefepime	>= 512	R	Cefepime	64	Resistant	Ciprofloxacin	>= 320	R	Aztreonam	-	-			
Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	Interpretation																																																		
ESBL	-	Inactive	Ampicillin	>= 16	R																																																		
Ampicillin	1	Intermediate	Ampicillin	>= 64	R																																																		
Ampicillin/Sulbactam	16	Intermediate	Piperacillin/Tazobactam	>= 16	R																																																		
Cefazolin	128	Resistant	Ceftazidime	>= 4	R																																																		
Ceftazidime	32	Resistant	Ceftriaxone	4	I																																																		
Ceftriaxone	64	Resistant	Cefepime	>= 512	R																																																		
Cefepime	64	Resistant	Ciprofloxacin	>= 320	R																																																		
Aztreonam	-	-																																																					
<p><b>Identification Information</b> Card: AST-C93 Lot Number: 2212813803 Exp.: 2 Aug 9, 2025 13:00 CST Status: Final Analysis Time: 5:78 hours Complet.: Apr 3, 2025 16:19 CDT Organism Origin: VITEK 2 Selected Organism: OXA-Producing Acinetobacter baumannii Biomarker: 024-00115502-0 Confidence: &gt; 95% identification Analysis Organisms and Tests in Separation: Acinetobacter baumannii Acinetobacter baumannii Analysis Messages: The following antibiotic(s) are inactive: ESBLs Contradicting/Typical Biopotency(s):</p>																																																							
<p><b>McFarland</b></p> <p><b>Susceptibility Information</b> Card: AST-C93 Status: Final Analysis Time: 12:21 hours Complet.: Apr 3, 2025 13:09 CST <table border="1"> <thead> <tr> <th>Antimicrobial</th> <th>MIC</th> <th>Interpretation</th> <th>Antimicrobial</th> <th>MIC</th> <th>Interpretation</th> </tr> </thead> <tbody> <tr> <td>ESBL</td> <td>-</td> <td>Inactive</td> <td>Ampicillin</td> <td>2</td> <td>S</td> </tr> <tr> <td>Ampicillin</td> <td>1</td> <td>Intermediate</td> <td>Ampicillin/Sulbactam</td> <td>&gt;= 2</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>16</td> <td>Intermediate</td> <td>Cefazolin</td> <td>&gt;= 1</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td>32</td> <td>Intermediate</td> <td>Ceftazidime</td> <td>&gt;= 4</td> <td>R</td> </tr> <tr> <td>Ceftazidime</td> <td>64</td> <td>Intermediate</td> <td>Ceftriaxone</td> <td>&gt;= 8</td> <td>R</td> </tr> <tr> <td>Ceftriaxone</td> <td>128</td> <td>Intermediate</td> <td>Cefepime</td> <td>&gt;= 20</td> <td>S</td> </tr> <tr> <td>Cefepime</td> <td>32</td> <td>Intermediate</td> <td>Ciprofloxacin</td> <td>&gt;= 320</td> <td>R</td> </tr> <tr> <td>Aztreonam</td> <td>-</td> <td>-</td> <td></td> <td></td> <td></td> </tr> </tbody> </table> <p><b>AES Finding:</b> Last Modified: Oct 3, 2024 14:36 CDT Parameter Set: Global CLSI 2024-based (Natural Resistance) Confidence Level: Consistent</p> </p>		Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	Interpretation	ESBL	-	Inactive	Ampicillin	2	S	Ampicillin	1	Intermediate	Ampicillin/Sulbactam	>= 2	S	Piperacillin/Tazobactam	16	Intermediate	Cefazolin	>= 1	S	Cefazolin	32	Intermediate	Ceftazidime	>= 4	R	Ceftazidime	64	Intermediate	Ceftriaxone	>= 8	R	Ceftriaxone	128	Intermediate	Cefepime	>= 20	S	Cefepime	32	Intermediate	Ciprofloxacin	>= 320	R	Aztreonam	-	-			
Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	Interpretation																																																		
ESBL	-	Inactive	Ampicillin	2	S																																																		
Ampicillin	1	Intermediate	Ampicillin/Sulbactam	>= 2	S																																																		
Piperacillin/Tazobactam	16	Intermediate	Cefazolin	>= 1	S																																																		
Cefazolin	32	Intermediate	Ceftazidime	>= 4	R																																																		
Ceftazidime	64	Intermediate	Ceftriaxone	>= 8	R																																																		
Ceftriaxone	128	Intermediate	Cefepime	>= 20	S																																																		
Cefepime	32	Intermediate	Ciprofloxacin	>= 320	R																																																		
Aztreonam	-	-																																																					
<p>Module: VITEK 2 System Version: 4.00 MIC Interpretation Code: Global CLSI 2024-based AES Parameter Set Name: Global CLSI 2024-based-Natural Resistance Page 1 of 2</p>																																																							
<p>Module: VITEK 2 System Version: 4.00 MIC Interpretation Code: Global CLSI 2024-based AES Parameter Set Name: Global CLSI 2024-based-Natural Resistance Page 1 of 2</p>																																																							
<p>Module: VITEK 2 System Version: 4.00 MIC Interpretation Code: Global CLSI 2024-based AES Parameter Set Name: Global CLSI 2024-based-Natural Resistance Page 1 of 2</p>																																																							
<p>Module: VITEK 2 System Version: 4.00 MIC Interpretation Code: Global CLSI 2024-based AES Parameter Set Name: Global CLSI 2024-based-Natural Resistance Page 1 of 2</p>																																																							

Installed: VITEK 2 System Version: 4.00.4  
MIC Interpretation Code: Global CLSI 2024-based  
AES Parameter Set Name: Global CLSI 2024-based-Natural Resistance  
Page 2 of 2

Installed: VITEK 2 System Version: 4.00.3  
MIC Interpretation Code: Global CLSI 2024-based  
AES Parameter Set Name: Global CLSI 2024-based-Natural Resistance  
Page 1 of 3

<p>Card Type: AST-GN93 Bar Code: 06129612032149 Testing Instrument: 00001C2A0179(25334)          Setup Technologist: Laboratory Test Unit LabTech          BioNumber: 0041-L-102500252          Organism Quantity: Selected Organism: <i>Pseudomonas aeruginosa</i>          Comments:</p>		<p>Card Type: AST-GN93 Bar Code: 06129612032149 Testing Instrument: 00001C2A0179(25334)          Setup Technologist: Laboratory Test Unit LabTech          BioNumber: 0041-L-102500000          Organism Quantity: Selected Organism: <i>Pseudomonas aeruginosa</i>          Comments:</p>																																																																																																							
<p><b>McFarland</b></p> <table border="1"> <tr> <td>Identification Information</td> <td>Card: GN</td> <td>Lot Number: 2412811503</td> <td>Expires: Aug 9, 2025 13:00 CDT</td> </tr> <tr> <td>Status: Final</td> <td>Analysis Time: 6.78 hours</td> <td colspan="2">Completed: Apr 2, 2025 16:08 CDT</td> </tr> <tr> <td>Organism Origin</td> <td>VITEK 2</td> <td colspan="2"></td> </tr> <tr> <td>Selected Organism</td> <td>99% Probability BioNumber: 0041-L-012451193100252</td> <td colspan="2"><i>Pseudomonas aeruginosa</i> Confidence: Very good identification</td> </tr> <tr> <td colspan="4">Analysis Organisms and Tests in Separate:</td> </tr> <tr> <td colspan="4">Analysis Messages: The following antibiotic(s) are not claimed: ESBLs.</td> </tr> <tr> <td colspan="4">Contradicting Typical Biopatterns:</td> </tr> <tr> <td colspan="4"> <p><b>McFarland</b></p> <table border="1"> <tr> <td>Susceptibility Information</td> <td>Card: AST-GN93</td> <td>Lot Number: 0612961203</td> <td>Expires: Jun 7, 2026 12:00 CST</td> </tr> <tr> <td>Status: Final</td> <td>Analysis Time: 15.08 hours</td> <td colspan="2">Completed: Apr 3, 2025 00:26 CDT</td> </tr> <tr> <td>Antimicrobial</td> <td>MIC</td> <td>Interpretation</td> <td>Antimicrobial</td> <td>MIC</td> <td>Interpretation</td> </tr> <tr> <td>ESBL</td> <td>-</td> <td>Intermediate</td> <td>Ampicillin</td> <td>&lt;= 0.25</td> <td>S</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>-</td> <td>Intermediate</td> <td>Ampicillin</td> <td>&lt;= 2</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>6</td> <td>S</td> <td>Ampicillin</td> <td>2-4</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td>-</td> <td>Intermediate</td> <td>Ampicillin</td> <td>&gt;= 8</td> <td>R</td> </tr> <tr> <td>Cefazidime</td> <td>8</td> <td>S</td> <td>Ampicillin</td> <td>-</td> <td>Intermediate</td> </tr> <tr> <td>Ceftriaxone</td> <td>-</td> <td>Intermediate</td> <td>Ampicillin</td> <td>-</td> <td>Intermediate</td> </tr> <tr> <td>Cefepime</td> <td>4</td> <td>S</td> <td>Ampicillin</td> <td>-</td> <td>Intermediate</td> </tr> <tr> <td>Aztreonam</td> <td>6</td> <td>I</td> <td>Ampicillin</td> <td>-</td> <td>Intermediate</td> </tr> </table> </td> </tr> <tr> <td>AES Findings:</td> <td colspan="3">Last Modified: Oct 3, 2024 14:56 CDT Parameter Set: Global CLSI 2024-based +Natural Resistance</td> </tr> <tr> <td>Confidence Level:</td> <td colspan="3">Consistent</td> </tr> </table>				Identification Information	Card: GN	Lot Number: 2412811503	Expires: Aug 9, 2025 13:00 CDT	Status: Final	Analysis Time: 6.78 hours	Completed: Apr 2, 2025 16:08 CDT		Organism Origin	VITEK 2			Selected Organism	99% Probability BioNumber: 0041-L-012451193100252	<i>Pseudomonas aeruginosa</i> Confidence: Very good identification		Analysis Organisms and Tests in Separate:				Analysis Messages: The following antibiotic(s) are not claimed: ESBLs.				Contradicting Typical Biopatterns:				<p><b>McFarland</b></p> <table border="1"> <tr> <td>Susceptibility Information</td> <td>Card: AST-GN93</td> <td>Lot Number: 0612961203</td> <td>Expires: Jun 7, 2026 12:00 CST</td> </tr> <tr> <td>Status: Final</td> <td>Analysis Time: 15.08 hours</td> <td colspan="2">Completed: Apr 3, 2025 00:26 CDT</td> </tr> <tr> <td>Antimicrobial</td> <td>MIC</td> <td>Interpretation</td> <td>Antimicrobial</td> <td>MIC</td> <td>Interpretation</td> </tr> <tr> <td>ESBL</td> <td>-</td> <td>Intermediate</td> <td>Ampicillin</td> <td>&lt;= 0.25</td> <td>S</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>-</td> <td>Intermediate</td> <td>Ampicillin</td> <td>&lt;= 2</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>6</td> <td>S</td> <td>Ampicillin</td> <td>2-4</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td>-</td> <td>Intermediate</td> <td>Ampicillin</td> <td>&gt;= 8</td> <td>R</td> </tr> <tr> <td>Cefazidime</td> <td>8</td> <td>S</td> <td>Ampicillin</td> <td>-</td> <td>Intermediate</td> </tr> <tr> <td>Ceftriaxone</td> <td>-</td> <td>Intermediate</td> <td>Ampicillin</td> <td>-</td> <td>Intermediate</td> </tr> <tr> <td>Cefepime</td> <td>4</td> <td>S</td> <td>Ampicillin</td> <td>-</td> <td>Intermediate</td> </tr> <tr> <td>Aztreonam</td> <td>6</td> <td>I</td> <td>Ampicillin</td> <td>-</td> <td>Intermediate</td> </tr> </table>				Susceptibility Information	Card: AST-GN93	Lot Number: 0612961203	Expires: Jun 7, 2026 12:00 CST	Status: Final	Analysis Time: 15.08 hours	Completed: Apr 3, 2025 00:26 CDT		Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	Interpretation	ESBL	-	Intermediate	Ampicillin	<= 0.25	S	Ampicillin/Sulbactam	-	Intermediate	Ampicillin	<= 2	S	Piperacillin/Tazobactam	6	S	Ampicillin	2-4	S	Cefazolin	-	Intermediate	Ampicillin	>= 8	R	Cefazidime	8	S	Ampicillin	-	Intermediate	Ceftriaxone	-	Intermediate	Ampicillin	-	Intermediate	Cefepime	4	S	Ampicillin	-	Intermediate	Aztreonam	6	I	Ampicillin	-	Intermediate	AES Findings:	Last Modified: Oct 3, 2024 14:56 CDT Parameter Set: Global CLSI 2024-based +Natural Resistance			Confidence Level:	Consistent		
Identification Information	Card: GN	Lot Number: 2412811503	Expires: Aug 9, 2025 13:00 CDT																																																																																																						
Status: Final	Analysis Time: 6.78 hours	Completed: Apr 2, 2025 16:08 CDT																																																																																																							
Organism Origin	VITEK 2																																																																																																								
Selected Organism	99% Probability BioNumber: 0041-L-012451193100252	<i>Pseudomonas aeruginosa</i> Confidence: Very good identification																																																																																																							
Analysis Organisms and Tests in Separate:																																																																																																									
Analysis Messages: The following antibiotic(s) are not claimed: ESBLs.																																																																																																									
Contradicting Typical Biopatterns:																																																																																																									
<p><b>McFarland</b></p> <table border="1"> <tr> <td>Susceptibility Information</td> <td>Card: AST-GN93</td> <td>Lot Number: 0612961203</td> <td>Expires: Jun 7, 2026 12:00 CST</td> </tr> <tr> <td>Status: Final</td> <td>Analysis Time: 15.08 hours</td> <td colspan="2">Completed: Apr 3, 2025 00:26 CDT</td> </tr> <tr> <td>Antimicrobial</td> <td>MIC</td> <td>Interpretation</td> <td>Antimicrobial</td> <td>MIC</td> <td>Interpretation</td> </tr> <tr> <td>ESBL</td> <td>-</td> <td>Intermediate</td> <td>Ampicillin</td> <td>&lt;= 0.25</td> <td>S</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>-</td> <td>Intermediate</td> <td>Ampicillin</td> <td>&lt;= 2</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>6</td> <td>S</td> <td>Ampicillin</td> <td>2-4</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td>-</td> <td>Intermediate</td> <td>Ampicillin</td> <td>&gt;= 8</td> <td>R</td> </tr> <tr> <td>Cefazidime</td> <td>8</td> <td>S</td> <td>Ampicillin</td> <td>-</td> <td>Intermediate</td> </tr> <tr> <td>Ceftriaxone</td> <td>-</td> <td>Intermediate</td> <td>Ampicillin</td> <td>-</td> <td>Intermediate</td> </tr> <tr> <td>Cefepime</td> <td>4</td> <td>S</td> <td>Ampicillin</td> <td>-</td> <td>Intermediate</td> </tr> <tr> <td>Aztreonam</td> <td>6</td> <td>I</td> <td>Ampicillin</td> <td>-</td> <td>Intermediate</td> </tr> </table>				Susceptibility Information	Card: AST-GN93	Lot Number: 0612961203	Expires: Jun 7, 2026 12:00 CST	Status: Final	Analysis Time: 15.08 hours	Completed: Apr 3, 2025 00:26 CDT		Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	Interpretation	ESBL	-	Intermediate	Ampicillin	<= 0.25	S	Ampicillin/Sulbactam	-	Intermediate	Ampicillin	<= 2	S	Piperacillin/Tazobactam	6	S	Ampicillin	2-4	S	Cefazolin	-	Intermediate	Ampicillin	>= 8	R	Cefazidime	8	S	Ampicillin	-	Intermediate	Ceftriaxone	-	Intermediate	Ampicillin	-	Intermediate	Cefepime	4	S	Ampicillin	-	Intermediate	Aztreonam	6	I	Ampicillin	-	Intermediate																																								
Susceptibility Information	Card: AST-GN93	Lot Number: 0612961203	Expires: Jun 7, 2026 12:00 CST																																																																																																						
Status: Final	Analysis Time: 15.08 hours	Completed: Apr 3, 2025 00:26 CDT																																																																																																							
Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	Interpretation																																																																																																				
ESBL	-	Intermediate	Ampicillin	<= 0.25	S																																																																																																				
Ampicillin/Sulbactam	-	Intermediate	Ampicillin	<= 2	S																																																																																																				
Piperacillin/Tazobactam	6	S	Ampicillin	2-4	S																																																																																																				
Cefazolin	-	Intermediate	Ampicillin	>= 8	R																																																																																																				
Cefazidime	8	S	Ampicillin	-	Intermediate																																																																																																				
Ceftriaxone	-	Intermediate	Ampicillin	-	Intermediate																																																																																																				
Cefepime	4	S	Ampicillin	-	Intermediate																																																																																																				
Aztreonam	6	I	Ampicillin	-	Intermediate																																																																																																				
AES Findings:	Last Modified: Oct 3, 2024 14:56 CDT Parameter Set: Global CLSI 2024-based +Natural Resistance																																																																																																								
Confidence Level:	Consistent																																																																																																								
<p>Installed VITEK 2 Systems Version: 9.06.4          MIC Interpretation Guideline: Global CLSI 2024-based          AES Parameter Set Name: Global CLSI 2024-based-Natural Resistance</p>		<p>Therapeutic Interpretation Guideline: NATURAL RESISTANCE          AES Parameter Set Name: Global CLSI 2024-based-Natural Resistance</p>																																																																																																							
<p>Installed VITEK 2 Systems Version: 9.06.4          MIC Interpretation Guideline: Global CLSI 2024-based          AES Parameter Set Name: Global CLSI 2024-based-Natural Resistance</p>																																																																																																									
<p>Comments:</p>		<p>Comments:</p>																																																																																																							
<p><b>McFarland</b></p> <table border="1"> <tr> <td>Susceptibility Information</td> <td>Card: AST-GN93</td> <td>Lot Number: 0612964203</td> <td>Expires: Jun 7, 2026 12:00 CST</td> </tr> <tr> <td>Status: Final</td> <td>Analysis Time: 14.43 hours</td> <td colspan="2">Completed: Apr 6, 2025 06:21 CDT</td> </tr> <tr> <td>Antimicrobial</td> <td>MIC</td> <td>Interpretation</td> <td>Antimicrobial</td> <td>MIC</td> <td>Interpretation</td> </tr> <tr> <td>ESBL</td> <td>-</td> <td>Intermediate</td> <td>Ampicillin</td> <td>1</td> <td>S</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>-</td> <td>Intermediate</td> <td>Ampicillin</td> <td>&gt;= 2</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>4</td> <td>S</td> <td>Ampicillin</td> <td>2-4</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td>&lt;= 1</td> <td>S</td> <td>Ampicillin</td> <td>&gt;= 8</td> <td>R</td> </tr> <tr> <td>Cefazidime</td> <td>&lt;= 1</td> <td>S</td> <td>Ampicillin</td> <td>-</td> <td>Intermediate</td> </tr> <tr> <td>Ceftriaxone</td> <td>4</td> <td>S</td> <td>Ampicillin</td> <td>-</td> <td>Intermediate</td> </tr> <tr> <td>Cefepime</td> <td>4</td> <td>S</td> <td>Ampicillin</td> <td>-</td> <td>Intermediate</td> </tr> <tr> <td>Aztreonam</td> <td>4</td> <td>S</td> <td>Ampicillin</td> <td>-</td> <td>Intermediate</td> </tr> </table>				Susceptibility Information	Card: AST-GN93	Lot Number: 0612964203	Expires: Jun 7, 2026 12:00 CST	Status: Final	Analysis Time: 14.43 hours	Completed: Apr 6, 2025 06:21 CDT		Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	Interpretation	ESBL	-	Intermediate	Ampicillin	1	S	Ampicillin/Sulbactam	-	Intermediate	Ampicillin	>= 2	S	Piperacillin/Tazobactam	4	S	Ampicillin	2-4	S	Cefazolin	<= 1	S	Ampicillin	>= 8	R	Cefazidime	<= 1	S	Ampicillin	-	Intermediate	Ceftriaxone	4	S	Ampicillin	-	Intermediate	Cefepime	4	S	Ampicillin	-	Intermediate	Aztreonam	4	S	Ampicillin	-	Intermediate																																								
Susceptibility Information	Card: AST-GN93	Lot Number: 0612964203	Expires: Jun 7, 2026 12:00 CST																																																																																																						
Status: Final	Analysis Time: 14.43 hours	Completed: Apr 6, 2025 06:21 CDT																																																																																																							
Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	Interpretation																																																																																																				
ESBL	-	Intermediate	Ampicillin	1	S																																																																																																				
Ampicillin/Sulbactam	-	Intermediate	Ampicillin	>= 2	S																																																																																																				
Piperacillin/Tazobactam	4	S	Ampicillin	2-4	S																																																																																																				
Cefazolin	<= 1	S	Ampicillin	>= 8	R																																																																																																				
Cefazidime	<= 1	S	Ampicillin	-	Intermediate																																																																																																				
Ceftriaxone	4	S	Ampicillin	-	Intermediate																																																																																																				
Cefepime	4	S	Ampicillin	-	Intermediate																																																																																																				
Aztreonam	4	S	Ampicillin	-	Intermediate																																																																																																				
AES Findings:	Last Modified: Oct 3, 2024 14:56 CDT Parameter Set: Global CLSI 2024-based +Natural Resistance																																																																																																								
Confidence Level:	Consistent																																																																																																								

<p>Installed VITEK 2 Systems Version: 9.06.4          MIC Interpretation Guideline: Global CLSI 2024-based          AES Parameter Set Name: Global CLSI 2024-based-Natural Resistance</p>		<p>Therapeutic Interpretation Guideline: NATURAL RESISTANCE          AES Parameter Set Name: Global CLSI 2024-based-Natural Resistance</p>																																																																		
<p>Installed VITEK 2 Systems Version: 9.06.4          MIC Interpretation Guideline: Global CLSI 2024-based          AES Parameter Set Name: Global CLSI 2024-based-Natural Resistance</p>																																																																				
<p>Comments:</p>		<p>Comments:</p>																																																																		
<p><b>McFarland</b></p> <table border="1"> <tr> <td>Susceptibility Information</td> <td>Card: AST-GN93</td> <td>Lot Number: 0612964203</td> <td>Expires: Jun 7, 2026 12:00 CST</td> </tr> <tr> <td>Status: Final</td> <td>Analysis Time: 8.30 hours</td> <td colspan="2">Completed: Apr 3, 2025 18:20 CDT</td> </tr> <tr> <td>Antimicrobial</td> <td>MIC</td> <td>Interpretation</td> <td>Antimicrobial</td> <td>MIC</td> <td>Interpretation</td> </tr> <tr> <td>ESBL</td> <td>NEG</td> <td>Cefoperazone</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>+Ampicillina</td> <td>-</td> <td>Aztreonam</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>Ampicillin</td> <td>&gt;= 32</td> <td>Tetracycline</td> <td>&gt;= 0.5</td> <td>S</td> </tr> <tr> <td>Ampicillin/Sulbactam</td> <td>8</td> <td>Merpempen</td> <td>&gt;= 0.25</td> <td>S</td> </tr> <tr> <td>Piperacillin/Tazobactam</td> <td>&lt;= 4</td> <td>S</td> <td>Merpempen</td> <td>&lt;= 2</td> <td>S</td> </tr> <tr> <td>Cefazolin</td> <td>-</td> <td>Ampicillin</td> <td>&lt;= 2</td> <td>S</td> </tr> <tr> <td>Ure</td> <td>&lt;= 4</td> <td>Gentamicin</td> <td>&lt;= 1</td> <td>S</td> </tr> <tr> <td>Other</td> <td>&lt;= 4</td> <td>Ciprofloxacin</td> <td>2</td> <td>S</td> </tr> <tr> <td>Ceftriaxone</td> <td>&lt;= 1</td> <td>Ciprofloxacin</td> <td>64</td> <td>I</td> </tr> <tr> <td>Ceftriaxone</td> <td>&lt;= 1</td> <td>Fimiclopram/ Sulfamethoxazole</td> <td>&gt;= 320</td> <td>R</td> </tr> </table>				Susceptibility Information	Card: AST-GN93	Lot Number: 0612964203	Expires: Jun 7, 2026 12:00 CST	Status: Final	Analysis Time: 8.30 hours	Completed: Apr 3, 2025 18:20 CDT		Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	Interpretation	ESBL	NEG	Cefoperazone	<= 1	S	+Ampicillina	-	Aztreonam	<= 1	S	Ampicillin	>= 32	Tetracycline	>= 0.5	S	Ampicillin/Sulbactam	8	Merpempen	>= 0.25	S	Piperacillin/Tazobactam	<= 4	S	Merpempen	<= 2	S	Cefazolin	-	Ampicillin	<= 2	S	Ure	<= 4	Gentamicin	<= 1	S	Other	<= 4	Ciprofloxacin	2	S	Ceftriaxone	<= 1	Ciprofloxacin	64	I	Ceftriaxone	<= 1	Fimiclopram/ Sulfamethoxazole	>= 320	R
Susceptibility Information	Card: AST-GN93	Lot Number: 0612964203	Expires: Jun 7, 2026 12:00 CST																																																																	
Status: Final	Analysis Time: 8.30 hours	Completed: Apr 3, 2025 18:20 CDT																																																																		
Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	Interpretation																																																															
ESBL	NEG	Cefoperazone	<= 1	S																																																																
+Ampicillina	-	Aztreonam	<= 1	S																																																																
Ampicillin	>= 32	Tetracycline	>= 0.5	S																																																																
Ampicillin/Sulbactam	8	Merpempen	>= 0.25	S																																																																
Piperacillin/Tazobactam	<= 4	S	Merpempen	<= 2	S																																																															
Cefazolin	-	Ampicillin	<= 2	S																																																																
Ure	<= 4	Gentamicin	<= 1	S																																																																
Other	<= 4	Ciprofloxacin	2	S																																																																
Ceftriaxone	<= 1	Ciprofloxacin	64	I																																																																
Ceftriaxone	<= 1	Fimiclopram/ Sulfamethoxazole	>= 320	R																																																																
AES Findings:	Last Modified: Oct 3, 2024 14:36 CDT Parameter Set: Global CLSI 2024-based +Natural Resistance																																																																			
Confidence Level:	Consistent																																																																			

<p>Installed VITEK 2 Systems Version: 9.06.4          MIC Interpretation Guideline: Global CLSI 2024-based          AES Parameter Set Name: Global CLSI 2024-based-Natural Resistance</p>		<p>Therapeutic Interpretation Guideline: NATURAL RESISTANCE          AES Parameter Set Name: Global CLSI 2024-based-Natural Resistance</p>	
<p>Installed VITEK 2 Systems Version: 9.06.4          MIC Interpretation Guideline: Global CLSI 2024-based          AES Parameter Set Name: Global CLSI 2024-based-Natural Resistance</p>			

**LAMPIRAN 6**  
**DOKUMENTASI PENELITIAN**

**Gambar Alat, Media, Reagensia dan Sampel Pemeriksaan**

**1. Alat**

Tabung Reaksi




Mikropipet 250  $\mu\text{L}$  dan 1000  $\mu\text{L}$



Tip 250  $\mu\text{L}$



Tip 1000  $\mu\text{L}$



Turbidimeter



Bunsen dan Mancis



Loop



Biosafety Cabinet



Inkubator




Mikroskop




VITEK 2 Compact



Komputer



Rak Tabung



## 2. Media dan Reagensia

NaCl 0,45%




Reagensia Pewarnaan Gram



Minyak Imersi



Media MacConkey Agar



Kartu VITEK



## 3. Sampel Pemeriksaan

Sampel Urin Penderita ISK




## Gambar Proses dan Hasil Penelitian


### 1. Proses Penelitian

Hari I : Penanaman pada Media Cled Agar dan MCA

Pengambilan Sampel Urin  
yang akan ditanam Ke  
Media



Inokulasi Sampel Pada Media  
MCA Dan CLED Agar



Hari II : Pewarnaan Gram, Identifikasi dan Uji Sensitivitas Menggunakan  
VITEK 2 Compact

a. Pewarnaan Gram

Pemanasan Ose diatas Api  
Bunsen



Pengambilan koloni pada  
media



**b. Identifikasi dan Uji Sentivitas**

Pengisian Saline Pada Tabung  
Untuk Identifikasi dan Uji  
Sensitivitas



Uji Kekeruhan Dengan Menggunakan  
Turbidimeter



Memasukkan Kartu VITEK  
Pada Masing Masing Tabung



Memasukkan Rak VITEK  
Berisi Tabung Dan Kartu  
VITEK ke Alat VITEK 2  
Compact




## 2. Hasil Penelitian


- a. Hasil Pembiakan Koloni  
Pertumbuhan Koloni Pada  
Media MCA



Pertumbuhan Koloni Pada Media CLED Agar



- a. Hasil Pewarnaan Gram



**LAMPIRAN 7**  
**RIWAYAT HIDUP PENULIS**

**Novia Rahma Bay**



Penulis lahir di Teluk Piai pada tanggal 19 November 2003. Penulis merupakan anak Ketiga dari empat bersaudara, putri dari pasangan Basri Jalaluddin dan Maimunah. Penulis memiliki seorang abang yang bernama Rofi Akbar Bay, kakak Qurnia Aini Bay dan seorang adik laki-laki Wahyu Afriza Bay. Perjalanan pendidikan penulis dimulai di SDN 112276 Teluk Piai, tempat penulis menempuh pendidikan dasar dari tahun 2011 hingga 2016. Setelah lulus SD, penulis melanjutkan ke jenjang pendidikan menengah pertama di SMPN 1 Kualuh Hilir dari tahun 2016 sampai 2019. Kemudian, penulis diterima di SMAN 1 Kualuh Hilir dan menyelesaikan pendidikan menengah atas pada tahun 2022. Berbekal semangat dan tekad yang kuat, penulis melanjutkan pendidikannya ke jenjang perguruan tinggi di Politeknik Kesehatan Kemenkes Medan. Di sana, penulis mengambil Jurusan Teknologi Laboratorium Medis dan berhasil menyelesaiannya pada tahun 2025.

## LAMPIRAN 8

### LEMBAR KARTU BIMBINGAN



#### KARTU BIMBINGAN KARYA TULIS ILMIAH TAHUN 2024/2025

Nama : Novia Rahma Bay  
NIM : P07534022079  
Nama Dosen Pembimbing : dr. Lestari Rahmah, MKT  
Judul : Identifikasi Bakteri Patogen pada Pasien penderita Infeksi Saluran Kemih (ISK) di Laboratorium Klinik Bunda Thamrin tahun 2025

No.	Hari/Tanggal Bimbingan	Materi Bimbingan	Paraf Dosen Pembimbing
1.	Kamis, 09 Januari 2025	Konsultasi Judul	✓
2.	Selasa, 14 Januari 2025	Pengajuan Judul	✓
3.	Kamis, 16 Januari 2025	Acc Judul	✓
4.	Jum'at, 24 Januari 2025	Pengajuan Bab 1	✓
5.	Rabu, 05 Februari 2025	Revisi Bab 1,2,3	✓
6.	Kamis, 12 Februari 2025	Revisi Bab 1,2,3	✓
7.	Selasa, 17 Februari 2025	Revisi Bab 1,2,3	✓
8.	Selasa, 20 Februari 2025	Revisi Bab 1,2,3	✓
9.	Senin, 24 Maret 2025	ACC Proposal	✓
10.	Rabu, 29 April 2025	Pengajuan Bab 4,5	✓
11.	Rabu, 8 Mei 2025	Revisi Bab 4,5	✓
12.	Rabu, 15 Mei 2025	Revisi Bab 4,5	✓
13.	Senin, 5 Juni 2025	Revisi Bab 4,5	✓
14.	Selasa, 12 Juni 2025	ACC KTI	✓

Diketahui oleh pembimbing,

dr. Lestari Rahmah, MKT

NIP. 197106222002122003

## LAMPIRAN 9

### TURNITIN

 turnitin Page 2 of 68 - Integrity Overview Submission ID trn:oid::1:3316803188

#### 14% Overall Similarity

The combined total of all matches, including overlapping sources, for each database.

##### Top Sources

11%	 Internet sources
2%	 Publications
9%	 Submitted works (Student Papers)

 turnitin Page 2 of 68 - Integrity Overview Submission ID trn:oid::1:3316803188

## Top Sources

11%  Internet sources  
2%  Publications  
9%  Submitted works (Student Papers)

## Top Sources

The sources with the highest number of matches within the submission. Overlapping sources will not be displayed.

1	 Internet	
	ecampus.poltekkes-medan.ac.id	2%
2	 Internet	
	repo.poltekkes-medan.ac.id	2%
3	 Student papers	
	Badan PPSDM Kesehatan Kementerian Kesehatan	1%
4	 Student papers	
	Fakultas Kedokteran Universitas Pattimura	<1%
5	 Internet	
	repository.unej.ac.id	<1%
6	 Internet	
	etheses.uin-malang.ac.id	<1%
7	 Student papers	
	Politeknik Kesehatan Kemenkes Padang	<1%
8	 Internet	
	locus.rivierapublishing.id	<1%
9	 Internet	
	repository.universitas-bth.ac.id	<1%
10	 Student papers	
	LPPM	<1%
11	 Internet	
	journal.sekawan-org.id	<1%

12	Internet	
tika-pratiwi.blogspot.com		<1%
13	Internet	
repository.uki.ac.id		<1%
14	Internet	
prosiding.aipatlmi-iasmlt.id		<1%
15	Internet	
repo.poltekkesdepkes-sby.ac.id		<1%
16	Student papers	
Universitas Riau		<1%
17	Internet	
text-id.123dok.com		<1%
18	Internet	
www.ukinstitute.org		<1%
19	Student papers	
Universitas Jambi		<1%
20	Student papers	
Academic Library Consortium		<1%
21	Student papers	
Pasundan University		<1%
22	Student papers	
Universitas Mulawarman		<1%
23	Student papers	
Padjadjaran University		<1%
24	Internet	
clinicaltrials.eu		<1%
25	Internet	
ejournal.stikstellamarismks.ac.id		<1%

26	Internet	
	repository.penerbiteureka.com	<1%
27	Student papers	
	State Islamic University Alauddin Makassar	<1%
28	Student papers	
	Universitas Negeri Jakarta	<1%
29	Internet	
	repository.um-surabaya.ac.id	<1%
30	Student papers	
	unimal	<1%
31	Student papers	
	Universitas Bengkulu	<1%
32	Student papers	
	Universitas PGRI Palembang	<1%
33	Internet	
	123dok.com	<1%
34	Student papers	
	Universitas Islam Riau	<1%
35	Internet	
	eprints.stikes-notokusumo.ac.id	<1%
36	Internet	
	poltekkesbdg.info	<1%
37	Internet	
	repository.dinamika.ac.id	<1%
38	Internet	
	repository.sari-mutriara.ac.id	<1%
39	Internet	
	www.scilit.net	<1%

40	Internet
docplayer.info	<1%
41	Internet
journal.iistr.org	<1%
42	Internet
medan.tribunnews.com	<1%
43	Internet
myhealthbox.eu	<1%
44	Internet
umu.diva-portal.org	<1%
45	Internet
digilib.esaunggul.ac.id	<1%
46	Internet
dspace.uii.ac.id	<1%
47	Internet
e-journals.dinamika.ac.id	<1%
48	Internet
edepot.wur.nl	<1%
49	Internet
eprints2.undip.ac.id	<1%
50	Internet
jahe.or.id	<1%
51	Internet
jambs.poltekkes-mataram.ac.id	<1%
52	Internet
www.researchgate.net	<1%
53	Internet
aanborneo.blogspot.com	<1%



Page 7 of 68 - Integrity Overview

Submission ID trn:oid::1:3316803188

54

Internet

repository.usd.ac.id

<1%



Page 7 of 68 - Integrity Overview

Submission ID trn:oid::1:3316803188